EGFR and glioblastoma: Group 1 is a group where the MNP with the αPD-1 checkpoint inhibitor mAb was used as a GBM suppressor, as we published [21], and group 2 represents mRNA therapeutics, anti-mouse AON against wild and mutated EGFR/EGFRvIII (one oligonucleotide was designed to suppress both gene variants) and anti-mouse AON against c-Myc.